Two-year results from the Phase 3 PROTECT trial evaluating sparsentan for IgA nephropathy were published on 2023-01-01. This randomized, active-controlled study compared the efficacy and safety of sparsentan against irbesartan in patients with the condition.
Background
The PROTECT trial investigated sparsentan for patients diagnosed with IgA nephropathy. This study aimed to assess its long-term effects in this patient population.
Trial design
The Phase 3 PROTECT trial was a randomized, active-controlled study designed to evaluate the efficacy and safety of sparsentan over a 2-year period. The trial compared sparsentan directly against irbesartan in patients with IgA nephropathy.
What this means
The publication of the 2-year results from the Phase 3 PROTECT trial provides clinicians and researchers with comprehensive data on the long-term efficacy and safety profile of sparsentan compared to irbesartan in patients with IgA nephropathy. This information is crucial for understanding the potential role of sparsentan in managing this progressive kidney disease and supports informed decision-making regarding treatment options.
Source
The information regarding these 2-year results was sourced from a publication on PubMed on 2023-01-01. The article, titled "Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 tri", is available on pubmed.ncbi.nlm.nih.gov.